Last update Aug. 19, 2021
Synthetic peptide similar to oxytocin, antagonist of human oxytocin receptors that inhibits uterine contractions.
Used as a tocolytic to stop premature labor.
Intravenous administration for a maximum of 48 hours.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
According to the manufacturer, small amounts of atosiban have been observed to pass from plasma into breast milk during breastfeeding (Accord 2015, EMA 2010).
Its pharmacokinetic data (large volume of distribution, high molecular weight and short half-life) make it unlikely that significant quantities will pass into breast milk.
Its low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.
In review papers and clinical trials with atosiban, no effects on breastfeeding were observed (Lopez 2018, Accord 2015, EMA 2010).
We do not have alternatives for Atosiban.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM